Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?

Amgen is advancing its experimental obesity drug, MariTide, into Phase III studies, aiming to secure a position in the burgeoning $100 billion obesity market by 2030. MariTide's potential monthly or less frequent dosing distinguishes it from current weekly GLP-1 leaders Eli Lilly and Novo Nordisk, although its Phase II data showed up to 20% weight loss, which was at the lower end of investor expectations. Amgen's stock has gained 8.9% year-to-date, trades below the industry's valuation, and has seen rising 2025 and 2026 earnings estimates, positioning the company for its entry into this competitive space.

Analysis

Amgen is strategically positioning itself to capture a share of the burgeoning obesity market, projected by Goldman Sachs to reach $100 billion by 2030. The company's lead candidate, MariTide, offers a significant potential differentiator with its monthly or less frequent dosing schedule, a notable convenience advantage over the weekly injections from current market leaders Eli Lilly and Novo Nordisk. While MariTide has advanced to a comprehensive Phase III program, its Phase II data, showing up to approximately 20% weight loss in non-diabetic patients, landed at the lower end of investor expectations of 20-25%, introducing a degree of execution risk. Despite this, Amgen's fundamentals appear robust; the stock has risen 8.9% year-to-date, outperforming its industry, and trades at an attractive forward P/E of 13.26, which is below both the industry average of 14.87 and its own five-year mean. This valuation is further supported by upward revisions to consensus earnings estimates for 2025 and 2026, signaling analyst confidence in its future prospects.

Key Decisions for Investors

• Given the stock's valuation below industry and historical averages, coupled with rising earnings estimates, investors may consider the current price an attractive entry point ahead of potential obesity market entry.
• Closely monitor the MARITIME Phase III trial results, as MariTide's ultimate market share will depend on demonstrating competitive efficacy beyond the ~20% weight loss seen in Phase II, which was on the low end of expectations.
• Upcoming data readouts in the second half of the year for other Amgen obesity studies represent a near-term catalyst that could significantly influence the stock's trajectory ahead of the main Phase III results.
• Investors should remain aware of escalating competition from both established leaders like Eli Lilly and Novo Nordisk and emerging players like Viking Therapeutics, as clinical differentiation will be critical in this crowded space.